Literature DB >> 20647568

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia.

Geoffrey L Uy1, Andrew A Lane, John S Welch, Nicole R Grieselhuber, Jacqueline E Payton, Timothy J Ley.   

Abstract

Previous studies in our laboratory demonstrated that the azurophil granule protease neutrophil elastase (NE) cleaves promyelocytic leukemia-retinoic acid receptor (PML-RAR)α (PR), the fusion protein that initiates acute promyelocytic leukemia (APL). Further, NE deficiency reduces the penetrance of APL in a murine model of this disease. We therefore predicted that NE-mediated PR cleavage might be important for its ability to initiate APL. To test this hypothesis, we generated a mouse expressing NE-resistant PR. These mice developed APL indistinguishable from wild-type PR, but with significantly reduced latency (median leukemia-free survival of 274 days vs 473 days for wild-type PR, P < .001). Resistance to proteolysis may increase the abundance of full-length PR protein in early myeloid cells, and our previous data suggested that noncleaved PR may be less toxic to early myeloid cells. Together, these effects appear to increase the leukemogenicity of NE-resistant PR, contrary to our previous prediction. We conclude that NE deficiency may reduce APL penetrance via indirect mechanisms that are still NE dependent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647568      PMCID: PMC2981479          DOI: 10.1182/blood-2008-11-189282

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

2.  STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation.

Authors:  M L McLemore; S Grewal; F Liu; A Archambault; J Poursine-Laurent; J Haug; D C Link
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

3.  Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia.

Authors:  Michelle M Le Beau; Elizabeth M Davis; Bhumi Patel; Vernon T Phan; Jastinder Sohal; Scott C Kogan
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Commonly dysregulated genes in murine APL cells.

Authors:  Wenlin Yuan; Jacqueline E Payton; Matthew S Holt; Daniel C Link; Mark A Watson; John F DiPersio; Timothy J Ley
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

Review 5.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

6.  Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice.

Authors:  Andrew A Lane; Timothy J Ley
Journal:  Cell       Date:  2003-10-31       Impact factor: 41.582

7.  Immunodetection of multiple species of retinoic acid receptor alpha: evidence for phosphorylation.

Authors:  M P Gaub; C Rochette-Egly; Y Lutz; S Ali; H Matthes; I Scheuer; P Chambon
Journal:  Exp Cell Res       Date:  1992-08       Impact factor: 3.905

8.  High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

Authors:  Peter Westervelt; Andrew A Lane; Jessica L Pollock; Kristie Oldfather; Matthew S Holt; Drazen B Zimonjic; Nicholas C Popescu; John F DiPersio; Timothy J Ley
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.

Authors:  Louise M Kelly; Jeffrey L Kutok; Ifor R Williams; Christina L Boulton; Sonia M Amaral; David P Curley; Timothy J Ley; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.

Authors:  S C Kogan; D E Brown; D B Shultz; B T Truong; V Lallemand-Breitenbach; M C Guillemin; E Lagasse; I L Weissman; J M Bishop
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  7 in total

1.  PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.

Authors:  Chengli Song; Lina Wang; Xiaoyan Wu; Kai Wang; Dan Xie; Qi Xiao; Songyu Li; Kui Jiang; Lujian Liao; John R Yates; Jiing-Dwan Lee; Qingkai Yang
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

2.  PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice.

Authors:  John S Welch; Wenlin Yuan; Timothy J Ley
Journal:  J Clin Invest       Date:  2011-04       Impact factor: 14.808

Review 3.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

4.  Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

Authors:  Lukas D Wartman; John S Welch; Geoffrey L Uy; Jeffery M Klco; Tamara Lamprecht; Nobish Varghese; Rakesh Nagarajan; Timothy J Ley
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 5.  Histone proteolysis: a proposal for categorization into 'clipping' and 'degradation'.

Authors:  Maarten Dhaenens; Pieter Glibert; Paulien Meert; Liesbeth Vossaert; Dieter Deforce
Journal:  Bioessays       Date:  2014-10-28       Impact factor: 4.345

Review 6.  Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy.

Authors:  Orsola di Martino; John S Welch
Journal:  Cancers (Basel)       Date:  2019-12-01       Impact factor: 6.639

7.  Notch signaling in acute promyelocytic leukemia.

Authors:  Nicole R Grieselhuber; Jeffery M Klco; Angela M Verdoni; Tamara Lamprecht; Shawn M Sarkaria; Lukas D Wartman; Timothy J Ley
Journal:  Leukemia       Date:  2013-03-04       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.